It is estimated that the annual output of inactivated vaccine in Beijing Institute of Biological Products will reach 654.38+0.2 billion doses, and that in Wuhan Institute of Biological Products will reach 654.38+0 billion doses. In addition, the genetically engineered subunit vaccine is expected to enter clinical research in June of this year from 5438+ 10, and once it is successfully developed, it can be mass-produced quickly.
It is reported that on April 12, the inactivated COVID-19 vaccine developed by Wuhan Institute of Biological Products under Sinopharm entered the first and second phase of clinical research, and the clinical trial results were released on June 16. The results showed that the safety after vaccination was good, and no serious adverse reactions occurred. After inoculation with different procedures and doses, the vaccinators all produced high titer antibodies.
Extended data:
Market price of inactivated vaccine:
"After the inactivated vaccine goes on the market, the price will not be very high. It is estimated that a needle costs several hundred dollars. If you take two, the price should be within 1000 yuan. " Liu Jingzhen, Party Secretary and Chairman of China Pharmaceutical Group Co., Ltd. said.
After a shot of vaccine, the protection rate is about 97%, and the antibody production is slow and grows slowly like a curve. Under normal circumstances, it will reach the level of anti-COVID-19 in about half a month; If two shots of vaccine are given, the protection rate can reach 100%.
Headline Outlook-The inactivated vaccine made in COVID-19 is expected to be available at the end of February.